Credit: Getty Images New research is being conducted on factor XI inhibitor therapy as the patent expiration for factor Xa inhibitors nears. Factor XI inhibitor therapy research is being conducted as ...

Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...

Treatment with the bleeding reversal agent andexanet (Andexxa) in people with acute intracerebral hemorrhage on factor Xa inhibitors led to less expansion of hematoma volume but was associated with ...

Please provide your email address to receive an email when new articles are posted on . In patients with nonvalvular atrial fibrillation receiving oral anticoagulants, factor Xa inhibitors appeared ...

"[...] this is the first study to address the effects of Xa-Is on composite cardiovascular events, congestive heart failure, arteriosclerotic disease, and ...

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

Among patients with atrial fibrillation (AF), use of factor Xa inhibitors for stroke prevention is associated with a greater risk of interstitial lung disease (ILD) than use of warfarin, although the ...

Background Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of ...

Factor XIa inhibitors milvexian and asundexian, hailed as the next-generation class of anticoagulants, earned mixed reviews on phase II data presented during the European Society of Cardiology ...

In patients with nonvalvular atrial fibrillation (NVAF), treatment with factor Xa (FXa) inhibitors was associated with a greater risk of interstitial lung disease (ILD) than other oral anticoagulants ...